View More Recent Stories
-
Johnson & Johnson (JNJ) Completes Acquisition of Proteologix
-
Johnson & Johnson (JNJ) Seeking FDA Approval of TREMFYA for Active Crohn's disease
-
Stifel Comments on Johnson & Johnson (JNJ) Post EU Robotic Tour: 'JNJ’s laparoscopic surgery business continues to be on the losing end of robotic share gain'
-
Johnson & Johnson (JNJ): Subcutaneous amivantamab BLA submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) reports TALVEY demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
-
BofA Securities Reiterates Neutral Rating on Johnson & Johnson (JNJ)
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) stock: 1Q24 earnings preview

